GlassScriptPhysician profile
Alejandro Montoya
NPI 1740719749
$6,794.60
in general payments reported to CMS, 2019-2025
42 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $426 · 2021: $956 · 2022: $1,271 · 2023: $1,401 · 2024: $1,484 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,015.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $780.35 | 2020-2025 | |
| Lilly USA, LLC | $770.81 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $750.37 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $593.18 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $568.62 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $505.88 | 2020-2025 | Farxiga, Lokelma, Breztri |
| Amgen INC. | $480.81 | 2020-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.80 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $262.60 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $153.94 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $128.40 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $124.99 | 2019 | |
| Sumitomo Pharma America, INC. | $100.34 | 2023-2025 | Gemtesa, Myfembree |
| Axsome Therapeutics, INC. | $97.74 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $97.12 | 2024-2025 | Voquezna |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Montoya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.